Novartis have announced that they are ending development of the drug branaplam in Huntington’s disease. Here, we review this latest news and its impact on the HD community.
Two recent studies show how a cellular border control system goes wrong in HD, opening new avenues for HD research.
Huntingtin helps fix damaged DNA, a recent study suggests, under the direction of a gene repair protein called ATM.
New technology enables researchers to find ultra-rare mutations in the HD gene, distinct from the one causing HD
New mouse model gives insights into Huntington's disease